Skip to Content

Easton Pharmaceuticals Inc EAPH

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

EAPH is trading at a 48% discount.
Price
$0.00
Fair Value
$8.54
Uncertainty
Extreme
1-Star Price
$6.14
5-Star Price
Economic Moat
Fxsm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EAPH is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.02
Market Cap
$1,344.93
Volume/Avg
38,700 / 65,110

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
6

Valuation

Metric
EAPH
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
EAPH
Quick Ratio
Current Ratio
Interest Coverage
Quick Ratio
EAPH

Profitability

Metric
EAPH
Return on Assets (Normalized)
−1.38%
Return on Equity (Normalized)
−2.69%
Return on Invested Capital (Normalized)
−1.51%
Return on Assets
EAPH
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
MKKGY
Merck KGaA ADRVkfnymqfwgZbrgpp$71.2 Bil
ZTS
Zoetis Inc Class AZpbyztvhzLpqh$68.3 Bil
HLN
Haleon PLC ADRGqhzxlyySgwr$37.0 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRFktlysktKtzh$14.5 Bil
VTRS
Viatris IncPxqhdqzddPql$13.4 Bil
RDY
Dr Reddy's Laboratories Ltd ADRSfptgmjCdsyq$11.9 Bil
CTLT
Catalent IncZxnctqbxxPjmrrfg$10.1 Bil
PRGO
Perrigo Co PLCHcmrbvfgyQtcp$4.1 Bil
CURLF
Curaleaf Holdings IncQqkvthncgHcwf$3.6 Bil
PBH
Prestige Consumer Healthcare IncZxvybjtcJbvmdf$3.5 Bil

Sponsor Center